You are here: Industry Insights > OSE Immunotherapeutics

News List

OSE Immunotherapeutics Receives Funding for Second Generation COVID-19 Vaccine americanpharmaceuticalreview
January 07, 2021
OSE Immunotherapeutics announces the Company has obtained funding of €5.2 million under the PSPC-COVID call for projects, operated on behalf of the French government by Bpifrance as part of the Programme d’investissements d’avenir (PIA) and led by the ...
OSE Provides Update on COVID-19 Vaccine americanpharmaceuticalreview
November 16, 2020
OSE Immunotherapeutics has announced successful completion of its human ex vivo study with CoVepiT, a prophylactic vaccine based on optimized epitopes selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2, the virus that ..
OSE Immunotherapeutics Receives Grant to Advance COVID-19 Vax contractpharma
July 17, 2020
OSE’s research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope-peptide approach.
OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program americanpharmaceuticalreview
May 11, 2020
OSE Immunotherapeutics announced its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.
OSE Immunotherapeutics updates licensing deal with Servier pharmaceutical-technology
March 19, 2020
OSE Immunotherapeutics has amended its global licensing option agreement with Servier for sole worldwide rights to OSE-127 in autoimmune diseases.
Boehringer Ingelheim and OSE Immunotherapeutics Ink $1.4B Deal biospace
April 08, 2018
Boehringer Ingelheim, headquartered in Ingelheim, Germany, and OSE Immunotherapeutics,based in Nantes, Frances, signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.